REGN - Regeneron Pharmaceuticals Stock Price, News & Analysis

$387.54 3.10 (0.81 %)
(As of 11/24/2017 04:03 AM ET)
Previous Close$384.44
Today's Range$384.50 - $388.39
52-Week Range$340.09 - $543.55
Volume367,500 shs
Average Volume897,789 shs
Market Capitalization$41.30 billion
P/E Ratio33.28
Dividend YieldN/A
Beta1.56

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:REGN
CUSIP75886F10

Debt

Debt-to-Equity Ratio0.12%
Current Ratio3.63%
Quick Ratio3.07%

Price-To-Earnings

Trailing P/E Ratio33.28
Forward P/E Ratio28.60
P/E Growth1.51

Sales & Book Value

Annual Sales$4.86 billion
Price / Sales8.57
Cash Flow$10.13 per share
Price / Cash38.27
Book Value$56.33 per share
Price / Book6.88

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$11.01
Net Income$895.52 million
Net Margins23.17%
Return on Equity25.73%
Return on Assets17.01%

Miscellaneous

Employees5,400
Outstanding Shares107,440,000

Frequently Asked Questions for Regeneron Pharmaceuticals (NASDAQ:REGN)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $3.83 by $0.16. The biopharmaceutical company had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business's revenue for the quarter was up 23.0% on a year-over-year basis. During the same period last year, the firm earned $3.13 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

When will Regeneron Pharmaceuticals make its next earnings announcement?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?

26 analysts have issued twelve-month price objectives for Regeneron Pharmaceuticals' stock. Their predictions range from $345.00 to $593.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $476.09 in the next twelve months. View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Regeneron’s third-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea’s sales. Eylea continues to perform well. Dupixent launch in the United States for moderate-to-severe atopic dermatitis is progressing well. The drug was also approved in Europe. The geographic expansion of the drug will further boost sales. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. The approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line and reduce the company’s dependence on Eylea for growth. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress payer utilization management restrictions in the United States." (11/14/2017)
  • 2. Canaccord Genuity analysts commented, "Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible." (10/16/2017)
  • 3. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
  • 4. Cowen Inc analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

  • P. Roy Vagelos M.D., Chairman of the Board (Age 87)
  • Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director (Age 64)
  • Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance (Age 53)
  • Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply (Age 44)
  • Neil Stahl Ph.D., Executive Vice President - Research and Development (Age 60)
  • Robert J. Terifay, Executive Vice President - Commercial (Age 57)
  • Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary (Age 58)
  • Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation (Age 46)
  • Peter Powchik M.D., Senior Vice President - Clinical Development (Age 60)
  • George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director (Age 57)

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Harding Loevner LP (3.42%), Janus Henderson Group PLC (1.44%), Artisan Partners Limited Partnership (1.38%), Polen Capital Management LLC (1.28%), Jennison Associates LLC (1.12%) and DSM Capital Partners LLC (0.99%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Polen Capital Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, Jennison Associates LLC, Sei Investments Co., Sectoral Asset Management Inc and State of Tennessee Treasury Department. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Harding Loevner LP, Old Mutual Global Investors UK Ltd., Assenagon Asset Management S.A., Orbimed Advisors LLC, AGF Investments Inc., Calamos Advisors LLC, Ardevora Asset Management LLP and First Trust Advisors LP. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $387.54.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $41.30 billion and generates $4.86 billion in revenue each year. The biopharmaceutical company earns $895.52 million in net income (profit) each year or $11.01 on an earnings per share basis. Regeneron Pharmaceuticals employs 5,400 workers across the globe.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-347-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (REGN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  988 (Vote Outperform)
Underperform Votes:  769 (Vote Underperform)
Total Votes:  1,757
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 14 Hold Ratings, 11 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $476.09 (22.85% upside)

Consensus Price Target History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Price Target History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Evercore ISILower Price TargetOutperform$605.00 -> $445.00N/AView Rating Details
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/AView Rating Details
11/9/2017Morgan StanleyLower Price TargetEqual Weight$490.00 -> $463.00N/AView Rating Details
11/9/2017Royal Bank Of CanadaReiterated RatingSector Perform -> Sector Perform$473.00 -> $425.00N/AView Rating Details
11/9/2017BMO Capital MarketsLower Price TargetMarket Perform$491.00 -> $479.00N/AView Rating Details
11/9/2017Citigroup Inc.Reiterated RatingBuy$480.00N/AView Rating Details
11/3/2017Robert W. BairdUpgradeUnderperform -> NeutralN/AView Rating Details
10/31/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
10/23/2017GuggenheimReiterated RatingBuy -> Buy$540.00N/AView Rating Details
10/20/2017Barclays PLCDowngradeEqual Weight -> Underweight$450.00 -> $395.00N/AView Rating Details
10/16/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
10/6/2017Jefferies Group LLCReiterated RatingHold$471.00 -> $500.00N/AView Rating Details
10/2/2017SunTrust Banks, Inc.Reiterated RatingHold$435.00MediumView Rating Details
9/27/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
9/11/2017Credit Suisse GroupReiterated RatingBuy$485.00LowView Rating Details
9/6/2017Raymond James Financial, Inc.Reiterated RatingOutperform -> Outperform$566.00LowView Rating Details
8/15/2017Leerink SwannReiterated RatingOutperform -> Positive$580.00 -> $552.00LowView Rating Details
8/9/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$469.00 -> $472.00LowView Rating Details
7/21/2017Bank of America CorporationReiterated RatingBuy$589.00 -> $593.00LowView Rating Details
6/30/2017BTIG ResearchReiterated RatingBuy -> Buy$480.00 -> $540.00HighView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00LowView Rating Details
5/15/2017Cowen IncReiterated RatingHold$380.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
1/10/2017Wells Fargo & CoReiterated RatingMarket PerformN/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
12/28/2016ArgusReiterated RatingBuy$450.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Regeneron Pharmaceuticals (NASDAQ:REGN)

Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Earnings History by Quarter for Regeneron Pharmaceuticals (NASDAQ REGN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018N/AView Earnings Details
11/8/2017Q3 2017$3.83$3.99$1.45 billion$1.50 billionViewN/AView Earnings Details
8/3/2017Q2 2017$2.67$4.17$1.36 billion$1.47 billionViewListenView Earnings Details
5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $13.55 EPS
Next Year EPS Consensus Estimate: $14.13 EPS

Dividends

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Regeneron Pharmaceuticals (NASDAQ REGN)

Insider Ownership Percentage: 10.80%
Institutional Ownership Percentage: 66.51%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ REGN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Michael S BrownDirectorSell1,500$475.00$712,500.00View SEC Filing  
9/29/2017Charles A BakerDirectorSell2,000$450.00$900,000.00View SEC Filing  
9/6/2017Robert E LandrySVPSell663$498.60$330,571.80View SEC Filing  
9/5/2017Robert E LandryCFOSell189$501.06$94,700.34View SEC Filing  
8/31/2017Robert E LandrySVPSell427$493.43$210,694.61View SEC Filing  
8/25/2017SanofiMajor ShareholderBuy72,378$481.36$34,839,874.08View SEC Filing  
8/24/2017SanofiMajor ShareholderBuy166,415$480.93$80,033,965.95View SEC Filing  
8/23/2017Robert E LandrySVPSell468$476.45$222,978.60View SEC Filing  
8/22/2017P Roy VagelosChairmanSell56,213$474.48$26,671,944.24View SEC Filing  
8/18/2017P Roy VagelosChairmanSell15,191$470.15$7,142,048.65View SEC Filing  
8/17/2017P Roy VagelosChairmanSell1,305$470.00$613,350.00View SEC Filing  
8/16/2017P Roy VagelosChairmanSell10,986$470.17$5,165,287.62View SEC Filing  
8/8/2017Robert E LandrySVPSell526$472.19$248,371.94View SEC Filing  
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.98View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.30View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.00View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.93View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.15View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.00View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.88View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.00View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.00View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.00View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.00View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.00View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Regeneron Pharmaceuticals (NASDAQ REGN)

Source:
DateHeadline
Regeneron Pharmaceuticals (REGN) a Hold on Poor Industry Group Rank - Investorplace.comRegeneron Pharmaceuticals (REGN) a Hold on Poor Industry Group Rank - Investorplace.com
investorplace.com - November 23 at 8:07 AM
Regeneron Pharmaceuticals is Now Oversold (REGN)Regeneron Pharmaceuticals is Now Oversold (REGN)
www.nasdaq.com - November 21 at 9:48 AM
Regeneron Pharmaceuticals (REGN) a Hold on Poor Industry Group RankRegeneron Pharmaceuticals (REGN) a Hold on Poor Industry Group Rank
investorplace.com - November 20 at 4:59 PM
Regeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $445.00 by Analysts at Evercore ISIRegeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $445.00 by Analysts at Evercore ISI
www.americanbankingnews.com - November 16 at 9:20 AM
Regeneron CEO: Competitor Novartis is 'long on enthusiasm...Regeneron CEO: Competitor Novartis is 'long on enthusiasm...
finance.yahoo.com - November 15 at 1:29 AM
Regeneron Pharmaceuticals: Cramers Top TakeawaysRegeneron Pharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - November 15 at 1:29 AM
Regeneron Pharmaceuticals, Inc. (REGN) Stock Rating Upgraded by Zacks Investment ResearchRegeneron Pharmaceuticals, Inc. (REGN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 14 at 1:58 PM
Weak Quant Score Restrict Regeneron Pharmaceuticals (REGN) Rating - Investorplace.comWeak Quant Score Restrict Regeneron Pharmaceuticals (REGN) Rating - Investorplace.com
investorplace.com - November 14 at 7:19 AM
Weak Quant Score Restrict Regeneron Pharmaceuticals (REGN) RatingWeak Quant Score Restrict Regeneron Pharmaceuticals (REGN) Rating
investorplace.com - November 13 at 4:24 PM
Regeneron Pharmaceuticals (REGN) "Buy" Rating Reaffirmed at Piper Jaffray CompaniesRegeneron Pharmaceuticals' (REGN) "Buy" Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - November 13 at 2:27 PM
SunTrust Banks Analysts Lift Earnings Estimates for Regeneron Pharmaceuticals, Inc. (REGN)SunTrust Banks Analysts Lift Earnings Estimates for Regeneron Pharmaceuticals, Inc. (REGN)
www.americanbankingnews.com - November 13 at 10:30 AM
Regeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $463.00 by Analysts at Morgan StanleyRegeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $463.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - November 9 at 8:54 PM
Regeneron Pharmaceuticals, Inc. (REGN) Issues  Earnings ResultsRegeneron Pharmaceuticals, Inc. (REGN) Issues Earnings Results
www.americanbankingnews.com - November 9 at 4:34 PM
Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted - NasdaqBiotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted - Nasdaq
www.nasdaq.com - November 9 at 12:24 PM
Regeneron Surrenders Most Early Gains After Q3 Beat - BenzingaRegeneron Surrenders Most Early Gains After Q3 Beat - Benzinga
www.benzinga.com - November 9 at 12:24 PM
Regeneron (REGN) Q3 Earnings Beat Estimates - NasdaqRegeneron (REGN) Q3 Earnings Beat Estimates - Nasdaq
www.nasdaq.com - November 9 at 12:24 PM
Heres Why Regeneron Pharmaceuticals Inc. Slipped 10% in October - Motley FoolHere's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October - Motley Fool
www.fool.com - November 9 at 12:24 PM
Did Regeneron Pharmaceuticals Inc (REGN) Create Value For Shareholders?Did Regeneron Pharmaceuticals Inc (REGN) Create Value For Shareholders?
finance.yahoo.com - November 9 at 12:24 PM
Regeneron sales jump 23 percent driven by Eylea and new eczema drugRegeneron sales jump 23 percent driven by Eylea and new eczema drug
finance.yahoo.com - November 9 at 12:24 PM
Regeneron Jumps After Issuing Street-Topping Revenue, EarningsRegeneron Jumps After Issuing Street-Topping Revenue, Earnings
finance.yahoo.com - November 9 at 12:24 PM
Regeneron President on Future of Health CareRegeneron President on Future of Health Care
finance.yahoo.com - November 9 at 12:24 PM
Edited Transcript of REGN earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of REGN earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 12:24 PM
Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold LiftedBiotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted
finance.yahoo.com - November 9 at 12:24 PM
When Will Biotech Bounce Back?When Will Biotech Bounce Back?
finance.yahoo.com - November 9 at 12:24 PM
BMO Capital Markets Trims Regeneron Pharmaceuticals, Inc. (REGN) Target Price to $479.00BMO Capital Markets Trims Regeneron Pharmaceuticals, Inc. (REGN) Target Price to $479.00
www.americanbankingnews.com - November 9 at 8:26 AM
Heres Why Regeneron Pharmaceuticals Inc. Slipped 10% in OctoberHere's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
www.fool.com - November 7 at 11:12 AM
Regeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial ... - StreetInsider.comRegeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial ... - StreetInsider.com
www.streetinsider.com - November 7 at 9:32 AM
Consolidated Research: 2018 Summary Expectations for Take-Two, CME Group, Intuit, Henry Schein, VeriSign, and ... - GlobeNewswire (press release)Consolidated Research: 2018 Summary Expectations for Take-Two, CME Group, Intuit, Henry Schein, VeriSign, and ... - GlobeNewswire (press release)
globenewswire.com - November 7 at 9:32 AM
Poor Quant Score Limit Regeneron Pharmaceuticals (REGN) Rating - Investorplace.comPoor Quant Score Limit Regeneron Pharmaceuticals (REGN) Rating - Investorplace.com
investorplace.com - November 7 at 9:32 AM
Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
finance.yahoo.com - November 7 at 9:31 AM
Consolidated Research: 2018 Summary Expectations for Take-Two, CME Group, Intuit, Henry Schein, VeriSign, and Regeneron – Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for Take-Two, CME Group, Intuit, Henry Schein, VeriSign, and Regeneron – Fundamental Analysis, Key Performance Indications
finance.yahoo.com - November 7 at 9:31 AM
Poor Quant Score Limit Regeneron Pharmaceuticals (REGN) RatingPoor Quant Score Limit Regeneron Pharmaceuticals (REGN) Rating
investorplace.com - November 6 at 7:18 PM
Regeneron Pharmaceuticals, Inc. (REGN) Receives Consensus Rating of "Hold" from AnalystsRegeneron Pharmaceuticals, Inc. (REGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 5 at 7:32 PM
Regeneron Pharmaceuticals, Inc. (REGN) Stock Rating Upgraded by Robert W. BairdRegeneron Pharmaceuticals, Inc. (REGN) Stock Rating Upgraded by Robert W. Baird
www.americanbankingnews.com - November 5 at 6:20 PM
Regeneron Pharmaceuticals, Inc. (REGN) Expected to Post Quarterly Sales of $1.46 BillionRegeneron Pharmaceuticals, Inc. (REGN) Expected to Post Quarterly Sales of $1.46 Billion
www.americanbankingnews.com - November 5 at 6:44 AM
Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings - BenzingaRegeneron Pharmaceuticals Gains A Bull Ahead Of Earnings - Benzinga
www.benzinga.com - November 4 at 10:54 AM
Regeneron to Share Clinical Progress of REGN1979 and ... - PR Newswire (press release)Regeneron to Share Clinical Progress of REGN1979 and ... - PR Newswire (press release)
www.prnewswire.com - November 1 at 3:35 PM
Inovio Pharma (INO) Initiates Study for Glioblastoma in Combination with Regenerons (REGN) PD-1 Inhibitor - StreetInsider.comInovio Pharma (INO) Initiates Study for Glioblastoma in Combination with Regeneron's (REGN) PD-1 Inhibitor - StreetInsider.com
www.streetinsider.com - November 1 at 3:35 PM
Quant Score Hurts Regeneron Pharmaceuticals (REGN) Rating - Investorplace.comQuant Score Hurts Regeneron Pharmaceuticals (REGN) Rating - Investorplace.com
investorplace.com - November 1 at 3:35 PM
Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual MeetingRegeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting
finance.yahoo.com - November 1 at 3:35 PM
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 InhibitorInovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
finance.yahoo.com - November 1 at 3:35 PM
Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by J P Morgan Chase & CoRegeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - November 1 at 1:22 PM
Regeneron And Sanofi Say Phase 3 Study On Dupilumab Meets Primary EndpointRegeneron And Sanofi Say Phase 3 Study On Dupilumab Meets Primary Endpoint
www.nasdaq.com - October 31 at 8:35 AM
Sanofi, Regenerons asthma trial results positiveSanofi, Regeneron's asthma trial results positive
www.marketwatch.com - October 31 at 8:35 AM
Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent AsthmaDupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma
finance.yahoo.com - October 31 at 8:34 AM
Quant Score Hurts Regeneron Pharmaceuticals (REGN) RatingQuant Score Hurts Regeneron Pharmaceuticals (REGN) Rating
investorplace.com - October 30 at 3:43 PM
Analyst Recommendations for Vertex Pharmaceuticals in OctoberAnalyst Recommendations for Vertex Pharmaceuticals in October
finance.yahoo.com - October 27 at 6:48 PM
Regenerons First Global Day of Service Supports Over 100 Non ... - PR Newswire (press release)Regeneron's First Global Day of Service Supports Over 100 Non ... - PR Newswire (press release)
www.prnewswire.com - October 27 at 1:43 PM
Relative Strength Alert For Regeneron Pharmaceuticals - NasdaqRelative Strength Alert For Regeneron Pharmaceuticals - Nasdaq
www.nasdaq.com - October 27 at 1:43 PM
Regenerons First Global Day of Service Supports Over 100 Non-Profit and Community OrganizationsRegeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations
finance.yahoo.com - October 27 at 1:43 PM

Social Media

Financials

Chart

Regeneron Pharmaceuticals (NASDAQ REGN) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.